|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-Part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lam JS, Shvarts O, Leppert JT, Pantuck AJ,
Figlin RA and Belldegrun AS: Postoperative surveillance protocol
for patients with localized and locally advanced renal cell
carcinoma based on a validated prognostic nomogram and risk group
stratification system. J Urol. 174:466–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McDermott DF, Regan MM, Clark JI, Flaherty
LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff
MS, et al: Randomized phase III trial of high-dose interleukin-2
versus subcutaneous interleukin-2 and interferon in patients with
metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005.
View Article : Google Scholar
|
|
7
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Motzer RJ, McCann L and Deen K: Pazopanib
versus sunitinib in renal cancer. N Engl J Med. 369:19702013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Escudier B, Pluzanska A, Koralewski P,
Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar
B, Bajetta E, et al: Bevacizumab plus interferon alfa-2a for
treatment of metastatic renal cell carcinoma: A randomised,
double-blind phase III trial. Lancet. 370:2103–2111. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: Efficacy of everolimus in advanced renal cell
carcinoma: A double-blind, randomised, placebo-controlled phase III
trial. Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hudes G, Carducci M, Tomczak P, et al:
Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choueiri TK, Escudier B, Powles T,
Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL,
Peltola K, et al: Cabozantinib versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1814–1823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Hutson TE, Glen H, Michaelson
MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B,
et al: Lenvatinib, everolimus, and the combination in patients with
metastatic renal cell carcinoma: A randomised, phase 2, open-label,
multicentre trial. Lancet Oncol. 16:1473–1482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jonasch E: NCCN guidelines updates:
Management of metastatic kidney cancer. J Natl Compr Canc Netw.
17:587–589. 2019.PubMed/NCBI
|
|
20
|
Albiges L, Powles T, Staehler M, Bensalah
K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, et
al: Updated european association of urology guidelines on renal
cell carcinoma: Immune checkpoint inhibition is the new backbone in
first-line treatment of metastatic clear-cell renal cell carcinoma.
Eur Urol. 76:151–156. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fuca G, de Braud F and Di Nicola M:
Immunotherapy-based combinations: An update. Curr Opin Oncol.
30:345–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Neill LA, Kishton RJ and Rathmell J: A
guide to immunome-tabolism for immunologists. Nat Rev Immunol.
16:553–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Donnell JS, Massi D, Teng MWL and
Mandala M: PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
Semin Cancer Biol. 48:91–103. 2018. View Article : Google Scholar
|
|
24
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sakaguchi S, Miyara M, Costantino CM and
Hafler DA: FOXP3+ regulatory T cells in the human immune system.
Nat Rev Immunol. 10:490–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bronte V, Brandau S, Chen SH, Colombo MP,
Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A,
Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived
suppressor cell nomenclature and characterization standards. Nat
Commun. 7:121502016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rini BI, Powles T, Atkins MB, Escudier B,
McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL,
et al: Atezolizumab plus bevacizumab versus sunitinib in patients
with previously untreated metastatic renal cell carcinoma
(IMmotion151): A multicentre, open-label, phase 3, randomised
controlled trial. Lancet. 393:2404–2415. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fridman WH, Pages F, Sautes-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kerkar SP and Restifo NP: Cellular
constituents of immune escape within the tumor microenvironment.
Cancer Res. 72:3125–3130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao W, Gu YH, Song R, Qu BQ and Xu Q:
Sorafenib inhibits activation of human peripheral blood T cells by
targeting LCK phosphorylation. Leukemia. 22:1226–1233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y,
Shu Y and Xu Q: Sunitinib impairs the proliferation and function of
human peripheral T cell and prevents T-cell-mediated immune
response in mice. Clin Immunol. 135:55–62. 2010. View Article : Google Scholar
|
|
34
|
Finke JH, Rini B, Ireland J, Rayman P,
Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and
Bukowski R: Sunitinib reverses type-1 immune suppression and
decreases T-regulatory cells in renal cell carcinoma patients. Clin
Cancer Res. 14:6674–6682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ko JS, Rayman P, Ireland J, Swaidani S, Li
G, Bunting KD, Rini B, Finke JH and Cohen PA: Direct and
differential suppression of myeloid-derived suppressor cell subsets
by sunitinib is compartmentally constrained. Cancer Res.
70:3526–3536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Adotevi O, Pere H, Ravel P, Haicheur N,
Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre
V, et al: A decrease of regulatory T cells correlates with overall
survival after sunitinib-based antiangiogenic therapy in metastatic
renal cancer patients. J Immunother. 33:991–998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huijts CM, Santegoets SJ, van den Eertwegh
AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM and van der
Vliet HJ: Phase I-II study of everolimus and low-dose oral
cyclophos-phamide in patients with metastatic renal cell cancer.
BMC Cancer. 11:5052011. View Article : Google Scholar
|
|
38
|
Beziaud L, Mansi L, Ravel P, Marie-Joseph
EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L,
Gamonet C, et al: Rapalogs efficacy relies on the modulation of
antitumor T-cell immunity. Cancer Res. 76:4100–4112. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huijts CM, Santegoets SJ, de Jong TD,
Verheul HM, de Gruijl TD and van der Vliet HJ: Immunological
effects of everolimus in patients with metastatic renal cell
cancer. Int J Immunopathol Pharmacol. 30:341–352. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Powell JD, Pollizzi KN, Heikamp EB and
Horton MR: Regulation of immune responses by mTOR. Annu Rev
Immunol. 30:39–68. 2012. View Article : Google Scholar
|
|
41
|
Chi H: Regulation and function of mTOR
signalling in T cell fate decisions. Nat Rev Immunol. 12:325–338.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Araki K, Turner AP, Shaffer VO, Gangappa
S, Keller SA, Bachmann MF, Larsen CP and Ahmed R: mTOR regulates
memory CD8 T-cell differentiation. Nature. 460:108–112. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rao RR, Li Q, Odunsi K and Shrikant PA:
The mTOR kinase determines effector versus memory CD8+ T cell fate
by regulating the expression of transcription factors T-bet and
Eomesodermin. Immunity. 32:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sadighi Akha AA: Aging and the immune
system: An overview. J Immunol Methods. 463:21–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mannick JB, Del Giudice G, Lattanzi M,
Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT,
Kovarik J, Carson S, et al: mTOR inhibition improves immune
function in the elderly. Sci Transl Med. 6:268ra1792014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Beziaud L, Boullerot L, Tran T, Mansi L,
Marie-Joseph EL, Ravel P, Johannes L, Bayry J, Tartour E and
Adotévi O: Rapalog combined with CCR4 antagonist improves
anticancer vaccines efficacy. Int J Cancer. 143:3008–3018. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kopecký O, Lukesová S, Vroblová V,
Vokurková D, Morávek P, Safránek H, Hlávková D and Soucek P:
Phenotype analysis of tumour-infiltrating lymphocytes and
lymphocytes in peripheral blood in patients with renal carcinoma.
Acta Medica (Hradec Kralove). 50:207–212. 2007. View Article : Google Scholar
|
|
48
|
Nixon AB, Schalper KA, Jacobs I, Potluri
S, Wang IM and Fleener C: Peripheral immune-based biomarkers in
cancer immunotherapy: Can we realize their predictive potential? J
Immunother Cancer. 7:3252019. View Article : Google Scholar : PubMed/NCBI
|
